Glycopyrronium Topical

Glycopyrronium topical is approved for one specific condition:

• Qbrexza (topical cloth): treatment of primary axillary hyperhidrosis (excessive underarm sweating with no underlying medical cause) in adults and in children and adolescents aged 9 years and older.

Glycopyrronium is an anticholinergic — it works by blocking acetylcholine receptors on sweat glands in the underarm. Acetylcholine is the chemical messenger your nervous system uses to tell those glands to produce sweat. When glycopyrronium blocks that receptor, the signal doesn't get through, and sweat production is reduced. Because it's applied directly to the skin, the effect is largely local rather than system-wide.

Qbrexza is applied topically to both underarms once daily using a single pre-moistened cloth. Apply it to clean, dry, unbroken skin. One cloth covers both underarms — wipe each side once. Do not apply it to other areas of the body, and do not use it more than once every 24 hours. Always wash your hands immediately after applying and discarding the cloth. Follow your prescriber's instructions for your specific situation.

The most common side effects reported in clinical trials include:

• Dry mouth (the most frequently reported, affecting roughly 1 in 4 users in trials)
• Dilated pupils (mydriasis) and blurred vision
• Difficulty starting to urinate (urinary hesitation)
• Headache
• Dry eyes, nasal dryness, and dry throat
• Constipation
• Dry skin
• Local skin reactions: redness (erythema), burning or stinging, and itching at the underarm application site

If you develop trouble urinating, stop sweating entirely in the heat, or experience blurred vision that does not go away, stop using Qbrexza and contact your doctor promptly.

• Urinary retention: Qbrexza can cause new or worsening difficulty passing urine, even in people with no prior history of urinary problems. Stop use immediately and call your doctor if you notice trouble urinating or a distended, uncomfortable bladder.
• Heat illness risk: Because this medicine reduces sweating, your body may struggle to cool down in hot or very warm conditions. Watch for a complete absence of sweating in the heat, which can lead to hyperpyrexia (dangerous overheating) or heat stroke. Avoid use if this happens.
• Blurred vision: Transient (temporary) blurred vision can occur. Do not drive, operate heavy machinery, or do hazardous work if your vision is affected. Stop use until vision clears.
• Accidental exposure — especially in children: Used cloths discarded in the trash have caused accidental eye exposure in children, leading to dilated pupils and blurred vision. Always wash hands after use and keep discarded cloths out of reach of children.

Qbrexza has one key interaction category to know about:

• Other anticholinergic medications: Taking Qbrexza alongside other drugs that have anticholinergic effects (such as certain medications for overactive bladder, some antihistamines, or some antidepressants) can add up the anticholinergic side effects — making dry mouth, urinary problems, blurred vision, and constipation more likely or more severe. Avoid combining them unless your doctor has reviewed your full medication list.

This is not a complete list of interactions. Always talk with your doctor or pharmacist before starting, stopping, or changing any medication.

• Do not use Qbrexza if you have glaucoma, myasthenia gravis (a nerve-muscle condition causing muscle weakness), a blocked bowel (paralytic ileus), severe ulcerative colitis or toxic megacolon, unstable cardiovascular status during acute bleeding, or Sjogren's syndrome.
• Tell your doctor if you have an enlarged prostate, bladder-neck obstruction, or any history of urinary retention — Qbrexza may worsen these conditions.
• Use with extra caution in hot weather or during exercise; reduced sweating raises the risk of overheating.
• Children under 9 years of age: safety and effectiveness have not been established.
• Older adults (65+): there is limited clinical trial data in this age group; use with care.
• Kidney disease: the body clears glycopyrronium much more slowly in people with kidney failure; tell your doctor if you have kidney problems.
• Pregnancy: there are no adequate human data on safety during pregnancy. Talk to your doctor before using Qbrexza if you are pregnant or planning to become pregnant.
• Breastfeeding: it is unknown whether glycopyrronium passes into breast milk. Discuss the benefits and risks with your doctor.

Using too much Qbrexza on the skin could increase local skin irritation and raise the risk of anticholinergic side effects such as dry mouth, urinary retention, flushing, rapid heartbeat, overheating, and dilated pupils. Applying it under tight or bandage-style dressings (occlusive conditions) may also cause increased absorption and stronger effects. If a severe or life-threatening reaction is suspected, seek emergency medical care immediately — treatment may include managing the individual symptoms and, in serious cases, a reversal agent called neostigmine.

After applying Qbrexza once daily to the underarms, glycopyrronium is absorbed through the skin and detectable in the bloodstream within about 1 to 1.5 hours on average, with no significant buildup over repeated daily use. Most of the drug is eliminated unchanged through the urine; only a small fraction is metabolized. In people with kidney failure, the body's ability to clear glycopyrronium is significantly reduced, which could increase exposure. The pharmacokinetics of Qbrexza have not been formally studied in people with liver problems or in pregnant women.

Store at room temperature 20° - 25°C (68° - 77°F); excursions permitted to 15° - 30°C (59° - 86°F) . keep away from heat or flame.